Aurobindo receives 7th approval from MCC South Africa

RELATED NEWS Aurobindo’s tally of USFDA approved cephs goes up Aurobindo Pharma: Good growth in US, EU Aurobindo Pharma Q3 net surges to Rs 60.1cr Aurobindo bags one more cephalosporin from USFDA ALSO READ See latest News about Aurobindo Pharm See previous management interviews See what other Experts & Brokerages are saying about Aurobindo Pharm Aurobindo Pharm BSE | NSE 13/02/12 Are Mutual Funds betting on Aurobindo Pharm?

Aurobindo Pharma Limited is delighted to announce that it has received another marketing authorization approval from Medicines Control Council (MCC) of South Africa. The Council has approved Lisinopril tablets in 5mg, 10mg and 20mg strengths. South African market is highly regulated and very important in its Geographical sphere. Aurobindo by virtue of this approval can now participate in one of the key segments of South African market.

 

Lisinopril is the generic version of Zestril marketed by Astra Zeneca.

 

Lisinopril Dihydrate is an effective, long acting orally administered ACE inhibitor. It is used often in the management of Hypertension. Lisinopril belongs to a class of drugs that today commands a market value of 27 Mio USD in South Africa.

  

Sourced From: Aurobindo Pharma Limited